New cryovials with integral septum for PfSPZ vaccine and PfSPZ challenge products
Official title: New cryovials with integral septum for cryopreservation of PfSPZ vaccine and PfSPZ challenge products.
Funded at Sanaria, INC. · NIH-11255658 · Data updated 2026-11-12
This grant funds the development of new cryovials to store malaria vaccines (PfSPZ) so they can be produced, tested, and used more reliably to help prevent malaria infections.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sanaria, INC. NIH-funded |
| Lab location | 1 site (Rockville, United States) |
| Project start | September 18, 2026 |
| Project end | August 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $1,000,000 |
| NIH project number | 1SB1AI195021-01 |
| Project ID | NIH-11255658 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals in malaria-endemic areas or travelers who may receive PfSPZ vaccines as part of clinical programs or future vaccination campaigns.
✕Less likely to help
Patients not enrolled in or near sites using PfSPZ vaccines or bypassing malaria vaccination programs may not directly benefit.
What this research studies
Sanaria aims to scale and improve its PfSPZ malaria vaccines by producing new cryovials with integral septa for cryopreservation. The work supports manufacturing and quality control to ensure vaccines and challenges stay viable for clinical testing and deployment. This project focuses on the packaging technology to enhance stability, transport, and accessibility of the PfSPZ products in malaria-endemic regions and research sites. The effort builds on prior vaccine data showing potential protection and aims to accelerate readiness for broader use and elimination programs.
Why it matters
Potential benefit: If successful, the new cryovials could improve vaccine stability and distribution, helping reduce malaria infections and transmission in affected populations.
How similar studies have gone: Previous malaria vaccine programs with PfSPZ have shown protective efficacy in multiple trials, supporting continued development.
Where this research is happening
-
Sanaria, INC.
Rockville, United States Active
Researchers
- Principal investigator: Hoffman, Stephen Lev — Sanaria, INC.
- Study coordinator: Hoffman, Stephen Lev
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.